Disclaimer: This information is educational and not legal advice. Cannabis laws are evolving at federal and state levels. Always consult qualified legal and healthcare professionals about your specific situation.
The “Big Beautiful Bill” (formally the One Big Beautiful Bill Act, Pub. L. 119–21), passed in July 2025, primarily affects the cannabis industry by creating significant market uncertainty, removing federal protections for state medical programs, and potentially banning many popular hemp-derived cannabinoid products.
The “One Big Beautiful Bill Act,” signed into law on July 4, 2025, represents a nearly 1,000-page federal budget package affecting tax rates to national security. While the bill doesn’t directly mention cannabis, several provisions may impact medical marijuana programs, hemp businesses, and the broader cannabis industry.
If you rely on state-legal medical cannabis programs that act within the law, knowing about these possible changes will help you deal with a changing situation.
The cannabis policy landscape is still complicated since federal law makes it illegal while states are legalizing it. The Big Beautiful Bill makes things even more complicated, so it’s important for patients and others in the industry to be up to date on how it can affect access to medical marijuana.
What is the Big Beautiful Bill?
The One Big Beautiful Bill Act functions as a federal budget reconciliation package determining how federal spending is allocated across government-funded programs and services.
The legislation also modifies tax rates for individuals and businesses across multiple sectors.
Federal budget packages commonly contain provisions that directly or indirectly impact specific industries through new policies and regulations. The Big Beautiful Bill follows this pattern, though its cannabis-related implications emerge more from what the bill excludes rather than what it explicitly includes.
At nearly 1,000 pages, the legislation addresses wide-ranging policy areas. The bill removed long-standing federal protections for state medical marijuana programs that had been included in previous appropriations legislation.
The Rohrabacher-Blumenauer Amendment
Since 2014, the Rohrabacher-Blumenauer Amendment (previously known as the Rohrabacher-Farr Amendment) has been included of federal spending legislation.
It stopped the Department of Justice from using federal money to get in the way of state medical cannabis programs that were following state law.
The amendment stopped federal prosecutors from going after medicinal marijuana businesses and patients in states where medical cannabis is permitted. This protection let medical marijuana markets grow and spread throughout more than 38 states without the constant apprehensions of federal enforcement measures.
Congressional leaders chose not to include the Rohrabacher-Blumenauer Amendment in the Big Beautiful Bill’s appropriations provisions. Cannabis policy experts describe this omission as putting state medical cannabis markets “in dire jeopardy.”
Without these federal protections, medical cannabis businesses face increased vulnerability to federal enforcement, even when operating in full compliance with state regulations. This uncertainty affects the entire medical marijuana ecosystem—from cultivators and dispensaries to patients who depend on legal access to cannabis medicine.
Potential business and patient impacts
- Investment challenges: Without federal protections, medical cannabis businesses may struggle to attract investors willing to accept increased federal enforcement risk. Reduced investment could impact business sustainability and operational costs.
- Product pricing: If businesses face higher costs due to investment challenges or increased legal uncertainty, these expenses may transfer to patients through higher product prices at dispensaries.
- Access concerns: Increased federal enforcement risk could potentially affect dispensaries operations, though the extent remains uncertain given limited federal resources and ongoing state-level commitment to medical programs.
- Operational uncertainty: Businesses operating compliantly under state law now face renewed questions about federal exposure, complicating long-term planning and expansion decisions.
What the Bill Doesn’t Address Directly
Cannabis banking reform delayed
The Big Beautiful Bill does not include provisions addressing cannabis banking challenges.
Currently, because cannabis remains federally illegal under Schedule I classification, financial institutions often hesitate to provide services to state-legal cannabis businesses.
This creates operational challenges including:
- Many cannabis businesses operating primarily on cash basis
- Difficulties with tax compliance and financial record-keeping
- Limited access to business loans and credit
- Challenges securing merchant services and payment processing
The Secure and Fair Enforcement Regulation (SAFER) Banking Act would provide federal protections to financial institutions serving state-legal cannabis businesses.
Congressional leaders have indicated readiness to advance SAFER Banking now that the Big Beautiful Bill has passed, though specific timelines remain uncertain.
Senator Bernie Moreno (R-OH), lead Republican sponsor of SAFER Banking, stated in June 2025 that cannabis banking reform discussions would likely resume “hopefully in the fall” after
Congress completes work on the budget bill (Marijuana Moment, June 2025).
Cannabis rescheduling remains stalled
The Big Beautiful Bill doesn’t address marijuana’s federal classification under the Controlled Substances Act. The rescheduling process, which would move cannabis from Schedule I to Schedule III, has remained in limbo since the Trump administration took office in January 2025.
Schedule III rescheduling would provide immediate tax relief for cannabis businesses by ending Section 280E restrictions that currently prevent standard federal tax deductions.
But this process operates separately from budget legislation and requires Drug Enforcement Administration action.
Hemp Industry Considerations
Current hemp status under the bill
In its enacted form, the Big Beautiful Bill does not directly affect the hemp industry or change existing hemp definitions under the 2018 Farm Bill. Hemp-derived products containing 0.3% THC or less remain federally legal under current law.
But separate legislation creates uncertainty for hemp businesses and consumers. The 2025 Agriculture Appropriations Bill, under consideration in Congress, contains language that would restrict hemp-derived products.
Proposed hemp restrictions in separate legislation
The Agriculture Appropriations Bill includes provisions that would:
Redefine hemp to exclude intoxicating cannabinoids: Products containing any “quantifiable” amount of THC would no longer qualify as legal hemp, banning:
- Hemp-derived delta-8 THC products
- Hemp-derived delta-9 THC products (currently legal under 0.3% threshold)
- THCA flower and vaporizer products
- Other hemp-derived intoxicating cannabinoids
If enacted, these restrictions include a one-year delay to allow industry adjustment.
The hemp market has grown substantially since 2018, with many businesses focusing on hemp-derived cannabinoid products. These proposed restrictions would fundamentally reshape the legal hemp industry.
The National Cannabis Industry Association opposes these provisions. Hemp-derived THC products are already widely available across the country. Despite legislators’ intent, this budget provision won’t change that fact. But it will ensure these products are made and sold without oversight.
What this Means for Medical Marijuana Patients
State medical marijuana programs continue operating under existing state laws and regulations. The Big Beautiful Bill doesn’t immediately change patient access to medical cannabis in states with established programs.
But the removal of federal protections creates a less certain legal environment. Patients should stay informed about developments in their specific states and maintain open communication with healthcare providers about their medical cannabis use.
Medical marijuana patients can support program stability by:
- Following all state program requirements carefully
- Maintaining current medical marijuana card registration
- Purchasing only from licensed, regulated dispensaries
- Staying within state possession limits
Keeping medical documentation current
Healthcare provider relationships
Discussing medical cannabis use with healthcare providers remains important for:
- Ensuring cannabis doesn’t interact with other medications
- Documenting therapeutic use for medical records
- Receiving guidance on appropriate product selection
- Monitoring treatment effectiveness
Ongoing Advocacy Efforts
Cannabis reform advocates continue working on federal policy improvements. The PREPARE Act, reintroduced in 2025 by Representatives Dave Joyce (R-OH) and Hakeem Jeffries (D-NY), aims to help federal agencies prepare for eventual cannabis policy reform.
Navigating Uncertainty with Professional Guidance
The Big Beautiful Bill creates a more uncertain federal environment for medical cannabis, primarily through the removal of long-standing protections for state programs.
But the legislation doesn’t immediately change state-level medical marijuana access or operations.
Understanding Your Medical Cannabis Options with Expert Support
Federal cannabis policy continues evolving, creating questions about access and program stability. While the Big Beautiful Bill’s omission of federal protections raises concerns, state medical marijuana programs remain committed to serving patients with qualifying conditions.
Staying informed about policy developments helps you make educated decisions about your healthcare. Understanding both federal and state-level cannabis regulations ensures you access medical marijuana safely and legally within your jurisdiction’s framework.
TeleLeaf connects patients with experienced healthcare providers who understand both the therapeutic potential of medical cannabis and the complex regulatory environment surrounding it.
Our knowledgeable team stays current on federal and state cannabis policy developments, helping you navigate an evolving legal landscape while accessing the medical marijuana that supports your health and wellbeing.
Through convenient telemedicine consultations, we evaluate qualifying conditions and guide you through your state’s medical marijuana card application process.
Schedule your consultation with TeleLeaf today to discuss whether medical marijuana might benefit your specific health needs.
Sources:
Ashlyn Saucier 
The One Big Beautiful Bill Act functions as a federal budget reconciliation package determining how federal spending is allocated across government-funded programs and services.
Current hemp status under the bill
Live Chat
